Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Study

Int J Cardiol. 2012 Oct 18;160(3):213-4. doi: 10.1016/j.ijcard.2012.06.015. Epub 2012 Jun 22.

Authors

Fabio Mangiacapra¹, Giuseppe Patti, Emanuele Barbato, Dejan Orlic, Aaron J Peace, Andrea D'Ambrosio, Miodrag Ostojic, William Wijns, Germano Di Sciascio

Affiliation

¹ Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy. f.mangiacapra@unicampus.it

PMID: 22727961
DOI: 10.1016/j.ijcard.2012.06.015

No abstract available

Publication types

Multicenter Study
Randomized Controlled Trial

MeSH terms

Angioplasty, Balloon, Coronary / adverse effects
Clopidogrel
Dose-Response Relationship, Drug
Humans
Internationality
Myocardial Infarction / drug therapy*
Myocardial Infarction / epidemiology
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors / administration & dosage*
Postoperative Complications / drug therapy*
Postoperative Complications / epidemiology
Prospective Studies
Ticlopidine / administration & dosage
Ticlopidine / analogs & derivatives*
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Clopidogrel
Ticlopidine